Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension
Completed · Phase 3 · Has a placebo group
Conditions studied: Hypertension
In brief
To demonstrate that Micardis and Norvasc when used together are more effective at lowering blood pre ssure.
Key facts
- Study ID
- NCT00281580
- Run by
- Boehringer Ingelheim
- People needed
- 1461
- Starts
- 2006-04-01
- Last updated by the study team
- 2014-03-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Main Inclusion Criteria: Male and female patients >=18 years of age with Stage I or II hypertension defined as: a mean seated cuff diastolic blood pressure >=95 and <=119 mmHg Main
You may not qualify if…
- Exclusion Criteria:
- Patient is pregnant; breast-feeding; unwilling to use birth control during the study; has secondary hypertension; severe renal dysfunction; hepatic insufficiency; stroke within the last six months; myocardial infarction, cardiac surgery, percutaneous transluminal coronary angioplasty, unstable angina or coronary artery bypass graft within the past three months; unstable or uncontrolled diabetes for the past three months defined as a glucosylates hemoglobin (HbA1c) greater than ten percent ; history of angioedema or hypersensitivity related to either study drug.
- Systolic Blood Pressure (SBP) is greater than or equal to 180 millimeters of mercury (mmHg), Diastolic Blood Pressure (DBP) is greater than or equal to 110 mmHg.
Where it is running
- 1235.1.368 Boehringer Ingelheim Investigational Site — Huntsville, Alabama, United States
- 1235.1.389 Boehringer Ingelheim Investigational Site — Huntsville, Alabama, United States
- 1235.1.411 Boehringer Ingelheim Investigational Site — Huntsville, Alabama, United States
- 1235.1.429 Boehringer Ingelheim Investigational Site — Chandler, Arizona, United States
- 1235.1.420 Boehringer Ingelheim Investigational Site — Tempe, Arizona, United States
- 1235.1.391 Boehringer Ingelheim Investigational Site — Cudahy, California, United States
- 1235.1.444 Boehringer Ingelheim Investigational Site — Encinitas, California, United States
- 1235.1.445 Boehringer Ingelheim Investigational Site — Encino, California, United States
- 1235.1.357 Boehringer Ingelheim Investigational Site — Long Beach, California, United States
- 1235.1.465 Boehringer Ingelheim Investigational Site — Los Angeles, California, United States
- 1235.1.441 Boehringer Ingelheim Investigational Site — Riverside, California, United States
- 1235.1.409 Boehringer Ingelheim Investigational Site — Sacramento, California, United States
- 1235.1.406 Boehringer Ingelheim Investigational Site — San Diego, California, United States
- 1235.1.414 Boehringer Ingelheim Investigational Site — Santa Ana, California, United States
- 1235.1.383 Boehringer Ingelheim Investigational Site — Spring Valley, California, United States
- 1235.1.395 Boehringer Ingelheim Investigational Site — Tustin, California, United States
- 1235.1.453 Boehringer Ingelheim Investigational Site — Milford, Connecticut, United States
- 1235.1.394 Boehringer Ingelheim Investigational Site — Newark, Delaware, United States
- 1235.1.354 Boehringer Ingelheim Investigational Site — Cooper City, Florida, United States
- 1235.1.451 Boehringer Ingelheim Investigational Site — DeLand, Florida, United States
- 1235.1.372 Boehringer Ingelheim Investigational Site — Fort Lauderdale, Florida, United States
- 1235.1.396 Boehringer Ingelheim Investigational Site — Fort Lauderdale, Florida, United States
- 1235.1.390 Boehringer Ingelheim Investigational Site — Hialeah, Florida, United States
- 1235.1.430 Boehringer Ingelheim Investigational Site — Kissimmee, Florida, United States
- 1235.1.457 Boehringer Ingelheim Investigational Site — Fairhope, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.